MORRIS PLAINS, N.J., Dec. 7, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that stockholders of the Company, at its 28th annual meeting, elected all seven nominees to serve as directors of the Company until the next annual meeting; approved the executive compensation by non-binding advisory vote; approved every one year as the frequency for the non-binding advisory vote on executive compensation by non-binding advisory vote; and ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the current fiscal year. Thereafter, the Board reappointed Dr. David M. Goldenberg as Chairman and Mr. Brian Markison as Lead Independent Director.
